Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1Carcinoma, Squamous Cell 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Excipients × Dermatologic × Clear all
NCT02844777 2023-01-12

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Vidac Pharma

Phase 2 Completed
93 enrolled 13 charts
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡